Azeliragon
- Generic Name
- Azeliragon
- Drug Type
- Small Molecule
- Chemical Formula
- C32H38ClN3O2
- CAS Number
- 603148-36-3
- Unique Ingredient Identifier
- LPU25F15UQ
- Background
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 297
- Registration Number
- NCT02916056
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 880
- Registration Number
- NCT02080364
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT00566397
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath